Celltrion Healthcare

South Korea's Celltrion Inc. has completed second-phase clinical trials of its COVID-19 treatment and is seeking conditional approval of its distr...

South Korea's biopharmaceutical firm Celltrion Inc. has completed the $278 million acquisition of Takeda Pharmaceutical Company Ltd's primary care a...

South Korea’s biopharmaceutical firm Celltrion Inc. can unveil an antibody treatment by around the end of the year that is able to kill the COVI...

South Korean biosimilar maker Celltrion Inc's operating profit topped market expectations by more than 20% in the third quarter, hitting a record high...

Seo Jung-jin, founder and chairman of South Korea’s biosimilar maker Celltrion Group, said on Oct. 6 that he is in talks with a number of global...

South Korea’s Celltrion Inc. and its affiliates are expected to post robust operating profits this year on the back of strong sales of Remsima a...

South Korea’s Celltrion Inc. on Sept. 10 rebutted J.P. Morgan’s massive downgrade of its target price for the biopharmaceutical company. T...

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...

One Equity Partners (OEP), a New York based private equity firm, unloaded its remaining shares in Celltrion Healthcare valued at approximately 31...

The National Pension Service (NPS) has put around 100 billion won ($93 million) into an equity stake in Dental Corporation, Canada’s largest net...

CVC Capital Partners is interested in electronic commerce, healthcare and services sectors in South Korea because of their growth potential, and willi...